Entecavir prevents HBV reactivation during direct acting antivirals for HCV/HBV dual infection: a randomized trial

A strategy to prevent hepatitis B virus (HBV) virologic reactivation (HBVr) and clinical reactivation (CR) during direct acting antiviral (DAA) treatment of hepatitis C virus (HCV)/HBV dual infection remains an unresolved issue.

Source: Clinical Gastroenterology and Hepatology - December 1, 2021 Category: Gastroenterology Authors: Pin-Nan Cheng, Chun-Jen Liu, Chi-Yi Chen, Kuo-Chih Tseng, Ching-Chu Lo, Cheng-Yuan Peng, Chih-Lin Lin, Hung-Chih Chiu, Yen-Cheng Chiu, Pei-Jer Chen Source Type: research